September 28, 2026

BSE Limited,
Floor 25, P. J. Towers
Dalal Street, Fort
Mumbai - 400 001

Scrip Code: 530019

National Stock Exchange of India Limited,
Exchange Plaza, Bandra-Kurla Complex,
Bandra (E),
Mumbai - 400051

Symbol: JUBLPHARMA

Sub.: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015

Dear Sirs,

With reference to the SEBI Master Circular HO/38/13/(4)2026-MIRSD-POD/I/4298/2026 dated February 6, 2026, attached is the specimen of the intimation sent today to those security holders whose final dividend for the financial year 2025-26 have been withheld due to non-submission of KYC documents.

The above information will also be available on the website of the Company at www.jubilantpharmova.com.

We request you to take the same on record.

Thanking you,

Yours faithfully,
For Jubilant Pharmova Limited

Naresh Kapoor
Digitally signed by Naresh Kapoor
Date: 2026.09.28 18:41:30 +05'30'

Naresh Kapoor
Company Secretary
Encl.: As above

Jubilant Pharmova Limited
1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantpharmova.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223
UP, India
CIN : L24116UP1978PLC004624

SPECIMEN LETTER

JUBILANT PHARMOVA LIMITED
(CIN: L24116UP1978PLC004624)
Regd. Office: Bhartiagram, Gajraula, District Amroha - 244223, Uttar Pradesh, India
Email: investors@jubl.com; **Website:** www.jubilantpharmova.com
Phone: +91-5924-267437

Folio No. Date:

Subject: Intimation regarding Non submission of KYC details in respect of physical shareholdings and withholding of final dividend payment for the financial year 2025-26

Ref: SEBI Master Circular No. HO/38/13/(4)2026-MIRSD-POD/I/4298/2026 dated February 6, 2026

Dear Member,

Pursuant to the SEBI Master Circular HO/38/13/(4)2026-MIRSD-POD/I/4298/2026 dated February 6, 2026, read with Regulation 12 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, payment of dividend through any mode other than electronic mode is discontinued. Accordingly, shareholders holding securities in physical form are required to ensure that the requisite KYC particulars are updated, including PAN, postal address, email address, mobile number, bank account details and specimen signature, as applicable, are registered in their folios.

As per the records of the Company/ Registrar & Share Transfer Agent (‘RTA”), the requisite KYC and/or bank account details in respect of your folio are incomplete or not updated. Consequently, the final dividend for the financial year 2025-26 payable in respect of your shareholding, as detailed below, has been withheld.

The dividend shall be remitted through electronic mode only after the requisite KYC and bank account details are registered and successfully validated in the records of the Company/RTA, subject to applicable tax requirements.

No. of equity shares held on record date i.e., on July 24, 2026	
Dividend per share (INR)	
Gross dividend amount (INR)	
Tax deducted at source (INR)	

Net dividend amount (INR)	
Rate at which tax is deducted (%)	
Payment date	
Status of Payment	
Reason of withholding	

For the purpose of updation of KYC details against your folio, you are requested to furnish duly filled documents / details as mentioned below:

a. Form ISR-1 for KYC update, along with self-attested supporting documents; and
b. Form ISR-2 for banker attestation of signature along with original cancelled cheque with your name(s) printed thereon or self-attested copy of bank passbook/statement; and
c. Form SH-13 for updation of Nomination for the aforesaid folio; or
d. Form ISR-3 for "Opt-out of the Nomination".

The aforesaid forms can be downloaded from the website of the Company https://www.jubilantpharmova.com/investors/investor-information/updation-of-kyc-details.

Kindly send self-attested hard copies of the aforesaid documents to our RTA at Alankit Assignments Limited, 205-208, AnarKali Complex, Jhandewalan Extension, New Delhi -110 055, phone: +91 11 42541234, email: rta@alankit.com.

We request you to treat this as our intimation regarding the withholding of Final Dividend for the financial year 2025-26 and updation of KYC details as mandated by SEBI.

Thanking you,
Yours faithfully

For Jubilant Pharmova Limited

Sd/-
Naresh Kapoor
Company Secretary
Membership No. A11782